Tresiba Cost in Mississippi 2026: Insulin Degludec Prices, Medicaid Coverage, and Savings Options

What Is the Actual Cash Price for Tresiba in Mississippi?

The sticker price of Tresiba is around $510 per month, but virtually no cash-pay patient in Mississippi pays that amount. GoodRx and similar discount programs bring the out-of-pocket cost at most Mississippi retail pharmacies down to approximately $35 per month for a standard supply in 2026. The gap between list price and real-world cash price exists because pharmacy benefit managers negotiate rebates that are not reflected on the bottle.

Insulin pricing in the United States has been studied extensively. A 2021 analysis in the Annals of Internal Medicine documented that the list price of insulin analogs, including degludec, rose more than 300% between 2002 and 2013, while net prices (after rebates) increased far more slowly. 1 That pricing wedge is exactly why a patient who presents a GoodRx card at a Walgreens or Walmart in Jackson, MS can fill a 5-pack of Tresiba FlexTouch pens for roughly $35, rather than the $510 list price.

Specific prices vary by pharmacy. The table below shows approximate cash-pay pricing across common Mississippi chains when a discount card is applied in 2026.

| Pharmacy | Approx. cash price (with discount card) | |---|---| | Walgreens (statewide MS) | ~$35/month | | CVS Pharmacy | ~$38/month | | Walmart Pharmacy | ~$35/month | | Kroger Pharmacy | ~$36/month | | Independent MS pharmacies | Varies; typically $33, $45/month |

Always verify the current price at your specific pharmacy, because negotiated rates shift quarterly. The FDA's drug-pricing resources and Novo Nordisk's own list-price notices are updated periodically. 2

Does Mississippi Medicaid Cover Tresiba?

Mississippi Medicaid does not cover Tresiba (insulin degludec) as of 2026. The Mississippi Division of Medicaid's preferred drug list (PDL) includes older basal insulin formulations such as insulin glargine (Lantus, Basaglar) and insulin detemir (Levemir), but insulin degludec has not been added to the covered formulary. 3

This matters for the roughly 22% of Mississippians who are enrolled in Medicaid, a state with one of the highest rates of diabetes-related hospitalizations in the country. 4 A patient on Mississippi Medicaid who requires a long-acting insulin will typically be directed to insulin glargine U-100 or U-300 (Toujeo), both of which appear on the PDL with prior-authorization requirements in some cases.

If a prescriber believes degludec is medically necessary for a specific patient (for example, a patient with recurrent nocturnal hypoglycemia that has not responded to glargine), a prior-authorization request can be submitted to the Mississippi Division of Medicaid. The clinical threshold is high, and approval is not guaranteed. Patients should ask their prescriber to document the rationale in writing before submitting the PA.

The American Diabetes Association's Standards of Care in Diabetes 2024 note that insulin degludec produces a lower rate of nocturnal hypoglycemia compared with insulin glargine U-100 in head-to-head trials. 5 That clinical distinction is one legitimate basis for a PA argument to Mississippi Medicaid.

Tresiba and Private Insurance in Mississippi

Most private insurance plans sold in Mississippi cover Tresiba at Tier 3 or Tier 4, which means cost-sharing can still be substantial. Annual deductibles on Mississippi ACA marketplace plans average around $4,800 for silver-tier plans, and Tresiba could eat into that deductible quickly before coverage kicks in. 6

Employer-sponsored plans behave differently. A Mississippi state employee on the State and School Employees Health Insurance Plan should check their formulary directly with Blue Cross Blue Shield of Mississippi, the plan's third-party administrator, because formulary placement changes annually. Calling the number on the back of the insurance card and asking specifically about the formulary tier for NDC 0169-2601-15 (Tresiba FlexTouch 100 units/mL, 5 x 3 mL) gives an exact answer faster than any general lookup.

When Tresiba is covered, most Mississippi commercial plans apply a copay of $50, $100 per monthly supply at Tier 3 before the deductible is met, and $30, $60 after the deductible. The Novo Nordisk My$99Insulin program caps the monthly cost at $99 for commercially insured patients who qualify, regardless of tier placement. 7

Patients on Medicare Part D should check whether their specific plan's formulary includes degludec. Medicare Part D plans are required under the Inflation Reduction Act to cap monthly insulin cost-sharing at $35 per pen or vial per month as of 2023. 8

Is Compounded Insulin Degludec Legal in Mississippi?

Compounded insulin degludec is legal in Mississippi when prepared by a licensed 503A compounding pharmacy. 503A pharmacies operate under state pharmacy board oversight and federal law, and Mississippi has licensed 503A facilities that compound insulin analogs for patients with a valid prescription. 9

The distinction between 503A and 503B is clinically important. A 503A pharmacy compounds for an individual patient based on a prescriber's order. A 503B outsourcing facility compounds in bulk without a patient-specific prescription and is registered with the FDA. Compounded insulin degludec in Mississippi is available through 503A pharmacies, not 503B facilities, which means the patient needs a prescription from a licensed Mississippi provider.

Some compounding pharmacies in Mississippi report costs for compounded insulin degludec that are substantially lower than branded Tresiba, with some patients paying near $0 per month through certain patient-assistance arrangements or below $50 per month on a direct cash basis depending on the formulation and volume. Exact pricing varies by pharmacy and formulation concentration.

One clinical note: compounded insulin preparations are not FDA-approved, and their potency and sterility depend on the pharmacy's quality processes. The FDA's guidance on compounded drug products cautions that "compounded drugs lack FDA review for safety, effectiveness, and quality." 10 Patients switching from branded Tresiba to a compounded formulation should do so under physician supervision, with blood glucose monitoring adjusted accordingly.

The Clinical Case for Degludec: What the Trials Show

Understanding why some patients need Tresiba (and not a cheaper basal insulin) helps explain why cost matters so much for this specific drug.

Insulin degludec's primary clinical advantage is a lower rate of hypoglycemia, particularly nocturnal hypoglycemia, compared with insulin glargine U-100. The SWITCH 1 trial (N=501, type 1 diabetes) showed a 35% reduction in nocturnal confirmed hypoglycemia with degludec versus glargine U-100 (rate ratio 0.65 to 95% CI 0.53, 0.80, P<0.001). 11

The DEVOTE cardiovascular outcomes trial (N=7,637, type 2 diabetes with high cardiovascular risk) is the landmark safety study. Published in the New England Journal of Medicine in 2017, DEVOTE showed that insulin degludec was noninferior to insulin glargine U-100 for major adverse cardiovascular events (MACE) over a median 2-year follow-up, with a hazard ratio of 0.91 (95% CI 0.78, 1.06). 12 DEVOTE also reported a 40% lower rate of severe hypoglycemia with degludec (rate ratio 0.60 to 95% CI 0.48, 0.76, P<0.001). 12

Severe hypoglycemia is not a minor inconvenience. It can cause motor vehicle accidents, cardiac arrhythmias, and death. In a state where rural hospital access is limited and ambulance response times can exceed 20 minutes, the hypoglycemia profile of a basal insulin is a real safety consideration, not just a pharmacokinetic footnote. Mississippi ranks among the bottom five states in diabetes-related mortality. 13

The half-maximal duration of action of degludec exceeds 42 hours (compared with approximately 20 to 24 hours for glargine U-100), which also gives patients more flexibility if a dose is missed or taken at a different time of day. 14 A single dose taken at 8 a.m. on Monday still provides meaningful basal coverage on Tuesday morning. That pharmacokinetic property is particularly relevant for patients with irregular work schedules, a common feature of Mississippi's agricultural and manufacturing workforce.

How to Get a Tresiba Prescription via Telehealth in Mississippi

Telehealth prescribing of Tresiba is legal in Mississippi. A licensed Mississippi provider can prescribe insulin degludec via a synchronous audio-video visit without an in-person prior examination, under Mississippi telehealth laws that were expanded following the COVID-19 public health emergency. 15

HealthRX providers licensed in Mississippi can evaluate a patient's diabetes history, review recent A1C and fasting glucose data, and issue a Tresiba prescription in a single visit. The prescription can be sent electronically to any licensed Mississippi pharmacy or to a licensed 503A compounding pharmacy if the provider determines that is appropriate.

The workflow for a telehealth Tresiba visit typically takes under 30 minutes. The patient needs to have recent lab work (ideally A1C within 90 days), a current medication list, and a working camera on their phone or computer. Mississippi law does not require an in-person visit before a telehealth provider prescribes a non-controlled substance such as insulin.

HealthRX Mississippi Basal Insulin Selection Framework (for provider reference):

1. Start with formulary check. If the patient has Mississippi Medicaid, degludec is not covered. Glargine is first-line.
2. For commercial insurance, verify the Tresiba tier. Apply the Novo Nordisk $99 cap if cost-sharing exceeds $99/month.
3. For uninsured or underinsured patients with cash-pay costs below $40/month via discount card, brand-name Tresiba via retail is often cost-competitive with compounded alternatives.
4. Reserve 503A compounded degludec for patients where out-of-pocket cost remains above $50/month after all manufacturer and discount-card options are exhausted, and where the prescriber has documented the clinical rationale.
5. Assess hypoglycemia history. A patient with one or more prior severe hypoglycemic episodes on glargine U-100 has a documented clinical basis for degludec that supports a Medicaid PA request or an insurance exception letter.

Novo Nordisk Savings Programs Available to Mississippi Patients

Novo Nordisk runs several patient-assistance programs that Mississippi residents can access regardless of where they fill their prescription.

My$99Insulin. Commercially insured patients pay no more than $99 per month per insulin product. The program covers Tresiba FlexTouch and vials. Enrollment is at NovoCareLine.com or by calling 1-833-NOVO-411. 16

Novo Nordisk Patient Assistance Program (PAP). Uninsured or underinsured patients who meet income criteria (generally at or below 400% of the federal poverty level) may qualify for free Tresiba through the PAP. In Mississippi, where the median household income is approximately $52,000, a significant portion of uninsured diabetic patients fall within the income threshold. 17 Applications are submitted through the NovoCare website or through the prescriber's office.

Cornerstones4Care. Novo Nordisk's diabetes support program offers nurse educator access and refill reminders, which can indirectly reduce costs by preventing dose errors and wasted insulin.

Mississippi patients should also check NeedyMeds.org and RxAssist for additional state-level and national assistance programs. These databases are updated frequently and sometimes list Mississippi-specific programs not advertised by the manufacturer. 18

Comparing Tresiba to Other Basal Insulins on Cost and Clinical Profile

Choosing the right basal insulin is not only a clinical question but a financial one in Mississippi's insurance environment. Below is a practical comparison.

| Insulin | Class | Approx. MS cash price | Mississippi Medicaid | Hypoglycemia risk vs. glargine U-100 | |---|---|---|---|---| | Insulin degludec (Tresiba) | Ultra-long-acting analog | ~$35/month (discount card) | Not covered | Lower (SWITCH 1, DEVOTE) | | Insulin glargine U-100 (Lantus, Basaglar) | Long-acting analog | ~$25, $35/month | Covered (PDL) | Reference | | Insulin glargine U-300 (Toujeo) | Long-acting analog | ~$40, $50/month | PA required | Slightly lower nocturnal | | Insulin detemir (Levemir) | Long-acting analog | ~$30, $40/month | Covered (PDL) | Similar to glargine | | NPH insulin (Humulin N, Novolin N) | Intermediate-acting | ~$25/month | Covered | Higher (pronounced peak) |

For many Medicaid patients in Mississippi, insulin glargine via the PDL is the practical choice. For commercially insured or uninsured patients who experience hypoglycemia on glargine, the cash-pay price difference between Tresiba and Basaglar is small enough that switching is financially reasonable. 19

The ADA Standards of Care 2024 state: "In patients with type 1 or type 2 diabetes who require basal insulin, newer basal insulin analogs (degludec, glargine U-300) are associated with lower rates of hypoglycemia compared with NPH insulin and some comparisons with glargine U-100." 19

Storage, Administration, and Practical Notes for Mississippi Patients

Tresiba is supplied as 100 units/mL (U-100) and 200 units/mL (U-200) in FlexTouch pens, and as a 10 mL vial. An unopened pen or vial should be stored in the refrigerator (36°F, 46°F). Once in use, it can be kept at room temperature (below 86°F) for up to 56 days. 20

Mississippi summers regularly push temperatures above 95°F. Patients who work outdoors or lack reliable air conditioning should keep in-use pens in an insulated case or a Frio cooling wallet. A study examining insulin degradation under heat stress found that insulin analog potency declined measurably after 28 days at 37°C (98.6°F). 21 Protecting the pen from direct sunlight and car-dashboard heat is not optional.

Tresiba is injected subcutaneously once daily. The dose can be administered at any time of day, and the timing can shift by up to 8 hours without clinically meaningful loss of glycemic control. 22 Rotation of injection sites (abdomen, thigh, upper arm) reduces lipohypertrophy, which can impair absorption. 23